Application of sodium bicarbonate in preparation of MSLN-CAR-T solid tumor treatment enhancer

By adjusting the pH value of the culture medium and combining MSLN-CAR-T cells, the problem of poor efficacy of CAR-T cell therapy in the treatment of solid tumors has been solved, and the killing ability of solid tumor cells has been significantly improved. Treatment of these types of cancer provides new ways to treat new cancers.

CN119055679APending Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411309031.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing CAR-T cell therapy has problems such as antigen defects, antigen deletion, antigen heterogeneity, failure of T cell infiltration and immunosuppression of the microenvironment when treating solid tumors, resulting in poor efficacy, especially for cancers with high MSLN expression. Such as mesothelioma, breast cancer, ovarian cancer, lung cancer and pancreatic cancer, the efficacy is not satisfactory.

Method used

Sodium bicarbonate combined with MSLN-CAR-T cells were used to adjust the pH value of the culture medium to 7.4~8.5, and MSLN-CAR-T cells were added in a ratio of 1:1~1:10 to enhance the solid tumor cells. Killing effect.

Benefits of technology

It significantly improves the killing ability of MSLN-CAR-T cells to solid tumor cells, provides new treatment ideas, and lays the foundation for clinical solid tumor treatment, especially in triple-negative breast cancer, pancreatic cancer, ovarian cancer and lung cancer. Shows significant therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055679A_ABST
    Figure CN119055679A_ABST
Patent Text Reader

Abstract

The invention discloses application of sodium bicarbonate in preparation of a reinforcing agent for treating solid tumors by MSLN-CAR-T. After the solid tumors are treated by sodium bicarbonate, MSLN-CAR-T is used for treatment, so that the treatment effect of MSLN-CAR-T in the solid tumors is improved, a new thought is provided for treating the solid tumors by CAR-T, and a foundation is laid for clinical solid tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor treatment, and specifically to the application of sodium bicarbonate combined with MSLN-CAR-T in the preparation of drugs for treating solid tumors. Background Art

[0002] Sodium bicarbonate is widely used in clinical practice to treat metabolic acidosis, alkalinize urine, excessive gastric symptoms, and nonspecific drug poisoning. Some clinical trials use high-dose NaHCO3 to study safety and pain relief in cancer patients. In basic studies of prostate cancer, colorectal cancer, liver cancer, or spontaneous metastasis mouse models, oral NaHCO3 can increase the pH of the tumor environment, significantly prevent metastasis, and do not affect the growth of the primary tumor. The role of sodium bicarbonate in CAR-T therapy has not yet been studied.

[0003] Chimeric antigen receptor T (CAR-T) cells are modified with single-chain antibodies (scFvs) and T cell activation domains. When CAR is expressed on the T cell membrane, the genetically modified CAR-T cells can recognize tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs) expressed on target cells and initiate killing functions to eliminate cancer cells without interacting with the major histocompatibility complex (MHC). In recent years, CAR-T cells have achieved encouraging clinical results in the treatment of hematological tumors. However, solid tumors progress slowly, and CAR-T cell therapy for solid tumor treatment has many limitations, such as antigen deficiency, antigen loss, and loss, antigen heterogeneity, T cell infiltration failure, T cell exhaustion, and microenvironmental immunosuppression.

[0004] MSLN is a membrane glycoprotein expressed in normal mesothelial cells, but highly expressed in mesothelioma, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and other cancers. In addition, some antibody-based therapeutic drugs as well as vaccines and T-cell therapies targeting MSLN are undergoing clinical evaluation, but the results are not satisfactory. How to improve the efficacy of MSLN-CAR-T cells in the treatment of solid tumors needs further exploration. Summary of the invention

[0005] In view of this, one of the objects of the present invention is to provide an application of sodium bicarbonate in the preparation of an MSLN-CAR-T enhancer for the treatment of solid tumors; a second object of the present invention is to provide an application of sodium bicarbonate combined with MSLN-CAR-T in the preparation of a drug for the treatment of solid tumors.

[0006] In order to achieve the above object, the present invention provides the following technical solutions: Application of sodium bicarbonate in the preparation of MSLN-CAR-T enhancer for the treatment of solid tumors.

[0007] Preferably, the solid tumor is triple-negative breast cancer, pancreatic cancer, ovarian cancer, lung cancer or colorectal cancer.

[0008] Application of sodium bicarbonate combined with MSLN-CAR-T in the preparation of drugs for the treatment of solid tumors.

[0009] Preferably, the application is to adjust the pH to 7.4-8.5 with sodium bicarbonate, treat the cells with different pH values, and then add MSLN-CAR-T cells at a target-effect ratio of 1:1-1:10.

[0010] Preferably, the application of the present invention is drinking a 200 mM NaHCO3 solution and then injecting MSLN-CAR-T cells.

[0011] The beneficial effects of the present invention are as follows: the present invention provides a method and application of sodium bicarbonate and MSLN-CAR-T in the treatment of solid tumors, further improving the therapeutic effect of MSLN-CAR-T in solid tumors. It provides a new idea for CAR-T treatment of solid tumors and lays a foundation for clinical treatment of solid tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration: Figure 1 The positive rate of MSLN-CAR-T cells was detected by flow cytometry; Figure 2 MDA-MB-231 and HCC38 cells were pretreated with culture media with different pH values ​​for 48 h and then co-cultured with T cells or MSLN-CAR-T cells at an E:T ratio of 1:0.5, 1:1, 1:5, and 1:10 for 6 h. The cell killing efficiency was detected by LDH (A: MDA-MB-231; B: HCC38 cells; all experiments were performed at least three times, and representative data from one experiment are shown. Quantitative data are expressed as mean ± SD, and P values ​​were analyzed using unpaired two-tailed t-test).

[0013] Figure 3 In vivo imaging was used to detect the changes in transplanted tumors in MDA-MB-231 tumor-bearing mice 10, 14, 18, 20, and 22 days after inoculation. In vivo imaging was used to detect the changes in transplanted tumors in HCC38 tumor-bearing mice 10, 14, 18, 20, and 22 days after inoculation.

[0014] Figure 4 Flow cytometry was used to detect the positive rate of MSLN-CAR-T cells.

[0015] Figure 5PANC-1 and AsPC-1 cells were pretreated with medium of different pH values ​​for 48 h, and then co-cultured with T cells or MSLN-CAR-T cells at an E:T ratio of 1:1, 1:5, and 1:10 for 6 h. The cell killing efficiency was detected by LDH. All experiments were performed at least three times, and representative data from one experiment are shown. Quantitative data are expressed as mean ± SD, and P values ​​were analyzed using unpaired two-tailed t-test.

[0016] Figure 6 The live imaging was used to detect the changes of transplanted tumors in AsPC-1 tumor-bearing mice at 6, 11, 18, 21, and 26 days after inoculation; the live imaging was used to detect the changes of transplanted tumors in PANC-1 tumor-bearing mice at 6, 9, 13, 16, and 20 days after inoculation.

[0017] Figure 7 Flow cytometry was used to detect the positive rate of MSLN-CAR-T cells.

[0018] Figure 8 After SK-OV-3 cells were pretreated with medium of different pH values ​​for 48 h, they were co-cultured with T cells or MSLN-CAR-T cells at an E:T ratio of 1:1, 1:5, and 1:10 for 6 h, and the cell killing efficiency was detected by LDH. All experiments were performed at least three times, and representative data from one experiment are shown. Quantitative data are expressed as mean ± SD, and P values ​​were analyzed using unpaired two-tailed t-test.

[0019] Fig. 9 In vivo imaging was used to detect changes in transplanted tumors in SK-OV-3 tumor-bearing mice 6, 9, 13, 16, and 20 days after inoculation. DETAILED DESCRIPTION

[0020] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand it.

[0021] The reagents and article numbers used in the present invention are as follows: Ficoll (GE, 17144003); fetal bovine serum (Gibco / Life Technologies, 10099-141); interleukin-2 (IL-2; Proteintech, HZ-1015); CD3 / CD28 beads (1:3; B&L Biotechnology, GMP-TL601); polybrene (8 μg / mL; Beyotime, ST1380-10 g); MSLN-CAR vector purchased from Suzhou ICARTAB Company (LIC012A); Lipo3000 (Invitrogen, L3000015); Lenti-X (TaKaRa, 2109257A); HIVELISA kit (PerkinElmer, NEK050001KT); MSLN pe-conjugated antibody (RD, FAB32652P); protein L (Pierce, 2997)-streptavidin APC (Invitrogen, S21374); EGFR-FITC (ICARTAB, 21092702); sodium bicarbonate (Solebol); lactate dehydrogenase (LDH) assay kit (Beyotime, C0017); Matrigel (Biocoat, 356231); NOG mice (CIEA, Charles River); fluorescein (2 μg / 20 g; Promega, P1043).

[0022] The application of sodium bicarbonate and MSLN-CAR-T combined treatment of triple-negative breast cancer, the specific steps are as follows: (1) Preparation of MSLN-CAR-T cells A. Fresh blood was collected from healthy volunteers with informed consent. Ficoll was used to separate normal human peripheral blood mononuclear cells, and primary cells were cultured in 10% fetal bovine serum and 100 U / ml interleukin-2.

[0023] B. Activation of T cells in monocytes: T cells were activated using anti-human CD3 and CD28 antibodies and cultured in a medium containing 10% fetal bovine serum and 100 U / ml interleukin-2.

[0024] C. Preparation of MSLN-CAR-T cells: The MSLN-CAR vector (the second-generation MSLN-CAR vector contains a MSLN-specific target single-chain antibody with a CD8 signal sequence, two intracellular co-stimulatory signal regions (CD3ζ and 4-1BB), a CD8 hinge region and a transmembrane sequence) and three auxiliary packaging plasmids (psPAX2, pRRE and pRSV-Rev) were transfected with Lipo3000, and the culture supernatant of HEK293T cells filtered for 48 or 72 h was collected, and the supernatant and the virus concentration reagent Lenti-X were added to the virus supernatant at a ratio of 3:1, centrifuged at 4°C and 4000g for 30 minutes, and resuspended to obtain the virus for use. The virus titer was determined using an HIV ELISA kit. Part of the T cells in the activated monocytes were inoculated into retronectin-coated culture plates, and the virus and polybrene were added, centrifuged at 32°C and 900g for 90 minutes, and incubated at 37°C for 24 hours; finally, MSLN-CAR-T cells were cultured in normal culture medium. Another part of the T cells in the activated monocytes were cultured as control group T cells.

[0025] D. Flow cytometry to detect the positive rate of MSLN-CAR-T: Cells were collected by centrifugation and washed twice with PBS; next, the cells were stained, precipitated and washed according to the antibody instructions; finally, the cells were incubated at 4°C in PBS containing 2% FBS for flow cytometry (BD, FACSAria II). The expression of MSLN on cancer cells was detected using human MSLN pe-conjugated antibody (RD, FAB32652P), and the expression of CAR on CAR-T cells was detected using EGFR-FITC and protein L-streptavidin APC. FlowJo 7.6.1 was used for data analysis. The results are shown in Figure 2. Figure 1 The results showed that the percentage of CAR-T cells expressing MSLN-scFv was approximately 33%.

[0026] (2) Preparation of triple-negative breast cancer cells Take out the cryopreservation tubes of MDA-MB-231 and HCC38 cells (human triple-negative breast cancer cell lines) from the liquid nitrogen tank, immediately place them in a 37°C water bath, shake them from time to time, and thaw them within 1 minute; wipe the surface of the cryopreservation tube clean, disinfect it with alcohol, and perform subsequent operations on the clean bench; transfer the cells in the cryopreservation tube into a 10ml centrifuge tube containing 5ml DMEM culture medium, and mix them with a glass dropper; place the 10ml centrifuge tube containing MDA-MB-231 and HCC38 cells in a horizontal centrifuge, centrifuge at 1200rpm / min for 10 minutes; discard the supernatant, add 5ml DMEM high-glucose (containing 10% fetal bovine serum by volume) complete culture medium, mix them with a glass dropper, and transfer the cells to a 50ml cell culture flask; culture them in an incubator at 37°C and a CO2 volume fraction of 5% for 12 hours.

[0027] (3) Effect of combined treatment with sodium bicarbonate and MSLN-CAR-T A. Treat tumor cells with sodium bicarbonate. Use sodium bicarbonate to adjust the pH of the culture medium to 6.5, 7.4, and 8.5. Add 2×10 4 MDA-MB-231 and HCC38 cells were seeded in 96-well plates and cultured in medium with different pH values ​​for 48 h.

[0028] B. In vitro killing: T cells and MSLN-CAR-T cells in the control group were collected and added to 96-well plates at ratios of 1:0.5, 1:1, 1:5 and 1:10 (target cells: effector cells) for 6 h. Target cells refer to tumor cells, and effector cells refer to T cells or MSLN-CAR-T cells. The level of lactate dehydrogenase (LDH) was determined using a kit. 10 μl of 10 × lysis buffer was added for 1 h. After centrifugation at 400 × g for 5 min, 60 μl of supernatant was transferred to a new plate and 60 μl of LDH working solution was added. The plate was incubated in the dark for 30 min, and the absorbance (OD) values ​​at 490 nm and 620 nm were detected. 4 to 5 replicates were used for each sample. The cytotoxicity (%) was calculated by the OD values ​​of the sample and the control, and the results are shown in the figure. Figure 2 As shown. The results showed that under the same pH culture conditions, there was no significant difference in the killing effect of untreated T cells on TNBC cells. The killing effect of MSLN-CAR-T cells on TNBC cells at pH 8.5 and pH 7.4 was higher than that at pH 6.5. Under alkaline conditions, the killing efficiency of MSLN-CAR-T cells on HCC38 cells was greatly increased to 80%.

[0029] C. In vivo killing: MDA-MB-231 and HCC38 cells carrying luciferase (1×10 6) was injected subcutaneously into the right side of female NOG mice at a ratio of 50:50 of Matrigel and PBS. NaHCO3 (200 mM) was added to the drinking water, and CAR-T cells (5×10 6 ). Mice were imaged 1 day before treatment, divided into groups of approximately equal tumor burden, randomly assigned to treatment groups, and kept blind until the end of the study. Imaging was performed after intraperitoneal injection of luciferin (2 μg / 20g), and tumor treatment effects were assessed by live mouse imaging (BLT, AniView100). Results are shown in Figure 3 As shown, the results showed that the fluorescence intensity of the treatment group treated with sodium bicarbonate was reduced, indicating that sodium bicarbonate can enhance the killing ability of MSLN-CAR-T against breast cancer cells.

[0030] This embodiment is the best embodiment of the present invention.

[0031] The application of sodium bicarbonate and MSLN-CAR-T combined treatment of pancreatic cancer, the specific steps are as follows: (1) Preparation of MSLN-CAR-T cells A. Fresh blood was collected from healthy volunteers with informed consent. Ficoll was used to separate normal human peripheral blood mononuclear cells, and primary cells were cultured in 10% fetal bovine serum and 100 U / ml interleukin-2.

[0032] B. Activation of T cells in monocytes. Microspheres coated with anti-human CD3 and CD28 antibodies were cultured in a medium containing 10% fetal bovine serum and 100 U / ml interleukin-2 to activate T cells.

[0033] C. Obtaining MSLN-CAR-T cells by lentiviral transduction of T cells The MSLN-CAR vector (the second-generation MSLN-CAR vector contains a msln-specific target single-chain antibody with a CD8 signal sequence, two intracellular co-stimulatory signal regions (CD3ζ and 4-1BB), a CD8 hinge region and a transmembrane sequence) and three auxiliary packaging plasmids (psPAX2, pRRE and pRSV-Rev) were transfected with Lipo3000. The culture supernatant of HEK293T cells filtered for 48 or 72 hours was collected, and the supernatant and the virus concentration reagent Lenti-X were added to the virus supernatant at a ratio of 3:1, centrifuged at 4°C and 4000g for 30 minutes, resuspended, and the virus was obtained for use. The virus titer was determined using an HIV ELISA kit. T cells from some activated monocytes were inoculated into retronectin-coated culture plates, and viruses and polybrene were added, centrifuged at 32°C and 900g for 90 minutes, and incubated at 37°C for 24 hours; finally, MSLN-CAR-T cells were cultured in normal culture medium. Another part of the activated monocytes T cells continued to be cultured as the control group T cells.

[0034] D. Flow cytometry was used to detect the positive rate of MSLN-CAR-T. The cells were collected by centrifugation and washed twice with PBS. Next, the cells were stained, precipitated and washed according to the antibody instructions. Finally, the cells were incubated at 4°C in PBS containing 2% FBS for flow cytometry (BD, FACSAria II). The expression of MSLN on cancer cells was detected using human MSLN pe-conjugated antibody (RD, FAB32652P). EGFR-FITC and protein L-streptavidin APC were used to detect CAR expression on CAR-t cells. Flow Jo7.6.1 was used for data analysis, and the results are shown in the figure. Figure 4 shown.

[0035] (2) Preparation of pancreatic cancer cells Take out the PANC-1 and AsPC-1 cell (human pancreatic cancer cell line) cryopreservation tubes from the liquid nitrogen tank, immediately place them in a 37°C water bath, shake them from time to time, and thaw them within 1 minute; wipe the surface of the cryopreservation tube clean, disinfect it with alcohol, and perform subsequent operations on the clean bench; transfer the cells in the cryopreservation tube into a 10ml centrifuge tube containing 5ml DMEM culture medium, and mix them with a glass dropper; place the 10ml centrifuge tube containing PANC-1 and AsPC-1 cells in a horizontal centrifuge, centrifuge at 1200rpm / min for 10 minutes; discard the supernatant, add 5ml DMEM high-glucose (containing 10% fetal bovine serum by volume) complete culture medium, mix them with a glass dropper, and transfer the cells to a 50ml cell culture flask; culture them in an incubator at 37°C and 5% CO2 by volume for 12 hours.

[0036] (3) Effect of combined treatment with sodium bicarbonate and MSLN-CAR-T A. Treat tumor cells with sodium bicarbonate. Use sodium bicarbonate to adjust the pH of the culture medium to 6.5, 7.4, and 8.5. Add 2×10 4 PANC-1 and AsPC-1 cells were seeded in 96-well plates and cultured in medium with different pH values ​​for 24 hours.

[0037] B. In vitro killing, T cells and MSLN-CAR-T cells were collected and added to 96-well plates at ratios of 1:1, 1:5 and 1:10 (target cells: effector cells) and cultured for 6 hours. The level of lactate dehydrogenase (LDH) was determined using a kit. After adding 10 μl of 10 × lysis buffer for 1 hour and centrifuging at 400 × g for 5 minutes, 60 μl of supernatant was transferred to a new plate and 60 μl of LDH working solution was added. The plate was incubated in the dark for 30 minutes, and the absorbance (OD) values ​​at 490 nm and 620 nm were detected. 4 to 5 replicates were used for each sample. The cytotoxicity (%) was calculated by the OD values ​​of the sample and the control. The results are shown in the figure. Figure 5 As shown. Under alkaline conditions, the killing efficiency of MSLN-CAR-T cells on AsPC-1 cells was greatly increased to 80%.

[0038] C. In vivo killing. 6 ) were injected subcutaneously into the right side of female NOG mice with Matrigel and PBS in a 50:50 ratio. NaHCO3 (200 mM) was added to the drinking water, and CAR-T cells (5×10 6 ). Mice were imaged 1 day before treatment, divided into groups of approximately equal tumor burden, randomly assigned to treatment groups, and kept blinded until the end of the study. Imaging was performed after intraperitoneal injection of luciferin (2 μg / 20 g), and tumor treatment effects were assessed by live mouse imaging (BLT, AniView100). Results are shown in Figure 6 The results showed that the fluorescence intensity of the treatment group treated with sodium bicarbonate was reduced, indicating that sodium bicarbonate can enhance the killing ability of MSLN-CAR-T against breast cancer cells.

[0039] The test results of this implementation are the same as those of Example 1.

[0040] The application of sodium bicarbonate and MSLN-CAR-T combined treatment of ovarian cancer, the specific steps are as follows: (1) Preparation of MSLN-CAR-T cells A. Fresh blood was collected from healthy volunteers with informed consent. Ficoll was used to separate normal human peripheral blood mononuclear cells, and primary cells were cultured in 10% fetal bovine serum and 100 U / ml interleukin-2.

[0041] B. Activation of T cells in monocytes. Microspheres coated with anti-human CD3 and CD28 antibodies were cultured in a medium containing 10% fetal bovine serum and 100 U / ml interleukin-2 to activate T cells.

[0042] C. Obtain MSLN-CAR-T cells by lentiviral transduction of T cells. The second-generation MSLN-CAR vector contains a msln-specific target single-chain antibody with a CD8 signal sequence, two intracellular co-stimulatory signal regions (CD3ζ and 4-1BB), a CD8 hinge region, and a transmembrane sequence. The virus was filtered and collected from the supernatant of HEK293T cells transfected with the MSLN-CAR vector and three auxiliary packaging plasmids (psPAX2, pRRE, and pRSV-Rev) for 48 or 72 h using Lipo3000. Lenti-X was added to the viral supernatant at a ratio of 3:1. The cells were resuspended in fresh culture medium at a ratio of 1:3 for later use. The virus titer was determined using an HIV ELISA kit.

[0043] D. Flow cytometry was used to detect the positive rate of MSLN-CAR-T. The cells were collected by centrifugation and washed twice with PBS. Next, the cells were stained, precipitated and washed according to the antibody instructions. Finally, the cells were incubated at 4°C in PBS containing 2% FBS for flow cytometry (BD, FACSAria II). The expression of MSLN on cancer cells was detected using human MSLN pe-conjugated antibody (RD, FAB32652P). EGFR-FITC and protein L-streptavidin APC were used to detect CAR expression on CAR- T cells. FlowJo 7.6.1 was used for data analysis, and the results are shown in the figure. Figure 7 shown.

[0044] (2) Preparation of ovarian cancer cells Take out the SK-OV3 cell (human ovarian cancer cell line) cryopreservation tube from the liquid nitrogen tank, immediately place it in a 37℃ water bath, shake it from time to time, and melt it within 1 minute; wipe the surface of the cryopreservation tube clean, disinfect it with alcohol, and then perform subsequent operations on the clean bench; transfer the cells in the cryopreservation tube into a 10ml centrifuge tube containing 5ml DMEM culture medium, and mix it with a glass dropper; place the 10ml centrifuge tube containing SK-OV3 cells in a horizontal centrifuge, centrifuge at 1200rpm / min for 10 minutes; discard the supernatant, add 5mlDMEM high-glucose (containing 10% fetal bovine serum by volume) complete culture medium, mix it with a glass dropper, and transfer the cells to a 50ml cell culture flask; culture it in an incubator at 37℃ and 5% CO2 by volume for 12 hours.

[0045] (3) Effect of combined treatment with sodium bicarbonate and MSLN-CAR-T A. Sodium bicarbonate treatment of tumor cells. Sodium bicarbonate was used to adjust the pH of the culture medium to 6.5, 7.4, and 8.5. 2×10 4 SK-OV3 cells were seeded in 96-well plates and cultured in medium with different pH values ​​for 24 hours.

[0046] B. In vitro killing. T cells and MSLN-CAR-T cells were collected and added to 96-well plates at ratios of 1:1, 1:5, and 1:10 (target cells: effector cells) and cultured for 6 h. The level of lactate dehydrogenase (LDH) was determined using a kit. After adding 10 μl of 10 × lysis buffer for 1 h, centrifugation at 400 × g for 5 min, 60 μl of supernatant was transferred to a new plate and 60 μl of LDH working solution was added. The plate was incubated in the dark for 30 min, and the absorbance (OD) values ​​at 490 nm and 620 nm were detected. 4 to 5 replicates were used for each sample. The cytotoxicity (%) was calculated by the OD values ​​of the sample and the control, and the results are shown in the figure. Figure 8 The results showed that the killing efficiency of MSLN-CAR-T cells on SK-OV3 cells was greatly improved.

[0047] C. In vivo killing. 6 ) SK-OV3 cells were subcutaneously injected into the right side of female NOG mice in a 50:50 ratio of Matrigel and PBS. NaHCO3 (200 mM) was added to the drinking water, and CAR-T cells (5×10 6). Mice were imaged 1 day before treatment, divided into groups of approximately equal tumor burden, randomly assigned to treatment groups, and kept blind until the end of the study. Imaging after intraperitoneal injection of luciferin (2 μg / 20 g) and tumor treatment efficacy were assessed by live mouse imaging (BLT, AniView100). The results are shown in Fig. 9 The results showed that the fluorescence intensity of the treatment group treated with sodium bicarbonate was reduced, indicating that sodium bicarbonate can enhance the killing ability of MSLN-CAR-T against ovarian cancer cells.

[0048] The detection results obtained in this embodiment are the same as those in embodiment 1.

[0049] Since MSLN is highly expressed in other solid tumors such as breast cancer, lung cancer, and colorectal cancer, and the MSLN target was detected to be increased after pH treatment of colorectal cancer and lung cancer, it is speculated that the combination therapy of sodium bicarbonate and MSLN-CAR-T can be used for the treatment of colorectal cancer and lung cancer.

[0050] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. Application of sodium bicarbonate in the preparation of MSLN-CAR-T enhancer for the treatment of solid tumors.

2. The use according to claim 1, characterized in that: The solid tumor is triple-negative breast cancer, pancreatic cancer, ovarian cancer, lung cancer or colorectal cancer.

3. Application of sodium bicarbonate combined with MSLN-CAR-T in the preparation of drugs for the treatment of solid tumors.

4. The use according to claim 3, characterized in that: The application is to adjust the pH to 7.4-8.5 with sodium bicarbonate, treat the cells with different pH values, and then add MSLN-CAR-T cells according to a target-effect ratio of 1:1-1:

10.

5. The use according to claim 3, characterized in that: The application is to drink a 200 mM NaHCO3 solution and then inject MSLN-CAR-T cells.

Citation Information

Cited By

  • Use of sodium bicarbonate in preparation of enhancer for MSLN-car-t treatment of solid tumors

    WO2026061439A1